NEW YORK ( TheStreet) -- Shares of Alexza Pharmaceuticals (Nasdaq: ALXA) were gapping down Friday morning with an open price 34.4% lower than Thursday's closing price. The stock closed at 61 cents Thursday and opened today's trading at 40 cents. The average volume for Alexza has been 1.3 million shares per day over the past 30 days. Alexza has a market cap of $80.1 million and is part of the health care sector and drugs industry. Shares are down 16.9% year to date as of the close of trading on Thursday. Alexza Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. TheStreet Ratings rates Alexza as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. You can view the full Alexza Ratings Report. Get more investment ideas from our investment research center.
More from Markets
Teva Shares Higher After Drugmaker Proposes $23B Global Opioid Settlement
The settlement, over and above an earlier agreement to settle with two Ohio counties, aims to resolve all outstanding opioid-related claims.
Stocks End Higher on Renewed Hope for U.S.-China Trade Pact, Earnings Optimism
Stocks finished higher Monday, bolstered by potential progress in the U.S.-China trade war and optimism about upcoming earnings reports.
Market Wrap: Muted Response to Trade Progress, Goldman Sachs Note on Buybacks
S&P 500 buybacks were down 18% in the second quarter according to a Goldman Sachs note.
How Investors Should Approach Positive Headlines Around U.S.-China Trade War
We're finally getting positive headlines around the U.S.-China trade war. Is it too soon to start celebrating?